Zeneca Acquires US Rights to Kadian, an Oral Morphine Product
WILMINGTON, Del--Zeneca Inc. has reached an agreement with Faulding Services Inc. (Adelaide, South Australia) for exclusive US rights to purchase, distribute, and promote Faulding's sustained-release morphine sulfate product Kadian, an oral medication taken once or twice daily.
WILMINGTON, Del--Zeneca Inc. has reached an agreement with FauldingServices Inc. (Adelaide, South Australia) for exclusive US rightsto purchase, distribute, and promote Faulding's sustained-releasemorphine sulfate product Kadian, an oral medication taken onceor twice daily.
A new drug application (NDA) for use of Kadian in the treatmentof moderate to severe chronic pain is currently under FDA review.The product is approved and available in Australia and severalEuropean countries.
